Compare Amgen, Inc. (AMGN) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Global X Robo Global Robotics & Automation ETF — how do they compare? Amgen, Inc. trades at $416.42 (market cap $224.14B), while Global X Robo Global Robotics & Automation ETF trades at $84.75. The key difference: Amgen, Inc. pays a 2.43% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | ROBO | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $417.20 | $90.34 |
52-Week Low | $271.18 | $62.34 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $84.79, up 1.59% with strong bullish technical signals from moving averages. The robotics ETF benefits from AI infrastructure expansion and recent sector momentum, though key valuation metrics remain undisclosed. Recent news highlights robotics as the next phase of AI investment beyond semiconductors, with thematic ETF comparisons favoring ROBO's diversified approach to automation exposure.
Outlook remains positive given structural AI adoption tailwinds, but elevated RSI levels suggest near-term consolidation risk. The ETF's 79-stock global portfolio offers diversified robotics exposure, though cyclical industrial dependencies and valuation concerns after recent rallies present balanced risk-reward dynamics for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
